Stockreport

Exact Sciences Advances Breast Cancer Care with the Oncotype DX® test and Genomic Profiling Research at SABCS 2024

Exact Sciences Corporation  (EXAS) 
Last exact sciences corporation earnings: 2/11 04:05 pm Check Earnings Report
PDF New data supports the value of the Oncotype DX Breast Recurrence Score® test in guiding treatment decisions, improving outcomes, and managing costs for breast cancer pat [Read more]